Idraparinux

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Idraparinux
Accession Number
DB06406
Type
Small Molecule
Groups
Investigational
Description
Not Available
Synonyms
Not Available
External IDs
SanOrg 34006 / SR 34006 / SR-34006
Product Ingredients
IngredientUNIICASInChI Key
Idraparinux SodiumH84IXP29FN149920-56-9Not applicable
Categories
UNII
6ADD3H8MFZ
CAS number
162610-17-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in thrombosis, venous thromboembolism, strokes, heart disease, and atrial fibrillation.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Idraparinux sodium is a novel long-acting synthetic highly potent synthetic and specific indirect inhibitor of coagulation factor Xa, injectable subcutaneously.

TargetActionsOrganism
UCoagulation factor XNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Idraparinux.Investigational
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Idraparinux.Approved, Investigational
AbciximabAbciximab may increase the anticoagulant activities of Idraparinux.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Idraparinux.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Idraparinux is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Idraparinux.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Idraparinux.Approved, Withdrawn
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Idraparinux.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Idraparinux.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Idraparinux.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Idraparinux.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Idraparinux.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Idraparinux.Approved
AltrenogestThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Altrenogest.Vet Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Idraparinux.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Idraparinux.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Idraparinux.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Idraparinux.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Idraparinux.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Idraparinux.Approved, Investigational
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Idraparinux.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Idraparinux.Approved
AncrodAncrod may increase the anticoagulant activities of Idraparinux.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Idraparinux.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Idraparinux.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Idraparinux.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Antithrombin III humanIdraparinux may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Idraparinux.Approved
ApocyninApocynin may increase the anticoagulant activities of Idraparinux.Investigational
ApremilastApremilast may increase the anticoagulant activities of Idraparinux.Approved, Investigational
ArdeparinArdeparin may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Idraparinux.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Idraparinux.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Idraparinux.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Idraparinux.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Idraparinux is combined with Azficel-T.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Idraparinux.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Idraparinux.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Idraparinux.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Idraparinux.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Idraparinux.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Idraparinux.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Idraparinux.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Idraparinux.Approved
BeraprostBeraprost may increase the anticoagulant activities of Idraparinux.Investigational
BevoniumBevonium may increase the anticoagulant activities of Idraparinux.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Idraparinux.Approved, Investigational
BoceprevirThe serum concentration of Idraparinux can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BrinaseBrinase may increase the anticoagulant activities of Idraparinux.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Idraparinux.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Idraparinux.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Idraparinux.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Idraparinux.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Idraparinux.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Idraparinux.Experimental
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Idraparinux.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Idraparinux.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Idraparinux.Approved
CangrelorCangrelor may increase the anticoagulant activities of Idraparinux.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Idraparinux.Investigational
CarbamazepineThe metabolism of Idraparinux can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Idraparinux.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Idraparinux.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Idraparinux.Approved, Investigational
CertoparinIdraparinux may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Idraparinux.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Idraparinux.Approved
CilostazolCilostazol may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Citric AcidCitric Acid may increase the anticoagulant activities of Idraparinux.Approved, Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Idraparinux.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Idraparinux.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Idraparinux.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Idraparinux.Approved
CloricromenCloricromen may increase the anticoagulant activities of Idraparinux.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Idraparinux.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Idraparinux is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Idraparinux.Approved
CurcuminCurcumin may increase the anticoagulant activities of Idraparinux.Approved, Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Idraparinux is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Idraparinux.Approved, Investigational, Vet Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Idraparinux.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Idraparinux.Experimental
DalteparinIdraparinux may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIdraparinux may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanIdraparinux may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Idraparinux.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Idraparinux is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Idraparinux.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Idraparinux.Approved
DemegestoneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Idraparinux is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Idraparinux.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Idraparinux.Approved, Investigational
DesirudinIdraparinux may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Idraparinux.Investigational
DesogestrelThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Desogestrel.Approved
DextranIdraparinux may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Idraparinux.Experimental
DiclofenacDiclofenac may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Idraparinux.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Idraparinux.Approved, Investigational
DienogestThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Idraparinux.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Idraparinux.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Idraparinux.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Idraparinux.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Idraparinux.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Idraparinux.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Idraparinux.Approved, Withdrawn
DiphenadioneDiphenadione may increase the anticoagulant activities of Idraparinux.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Idraparinux.Approved
DitazoleDitazole may increase the anticoagulant activities of Idraparinux.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Idraparinux.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Idraparinux.Approved, Investigational
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Idraparinux.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Idraparinux.Investigational
DydrogesteroneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Idraparinux.Approved
E-6201E-6201 may increase the anticoagulant activities of Idraparinux.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Idraparinux.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Idraparinux.Approved, Investigational
EnoxaparinEnoxaparin may increase the anticoagulant activities of Idraparinux.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Idraparinux.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Idraparinux.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Idraparinux.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Idraparinux.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Idraparinux.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Idraparinux.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Idraparinux.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Idraparinux.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Idraparinux.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Idraparinux.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Idraparinux.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Idraparinux.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Idraparinux.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Idraparinux.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Idraparinux.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Idraparinux.Approved, Investigational
EstriolEstriol may decrease the anticoagulant activities of Idraparinux.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Idraparinux.Approved
EstroneEstrone may decrease the anticoagulant activities of Idraparinux.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Idraparinux.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Idraparinux.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Idraparinux.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Idraparinux.Approved
Ethyl biscoumacetateIdraparinux may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Idraparinux.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Idraparinux.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Idraparinux.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Idraparinux.Investigational, Nutraceutical
ExisulindExisulind may increase the anticoagulant activities of Idraparinux.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Idraparinux.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Idraparinux.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Idraparinux.Approved
FentiazacFentiazac may increase the anticoagulant activities of Idraparinux.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Idraparinux.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Idraparinux.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Idraparinux.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Idraparinux.Approved, Withdrawn
FluindioneIdraparinux may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Idraparinux.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Idraparinux.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Idraparinux.Approved, Investigational
FondaparinuxIdraparinux may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Idraparinux.Approved, Investigational
GabexateIdraparinux may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Idraparinux can be decreased when it is combined with Garlic.Approved
GenisteinGenistein may decrease the anticoagulant activities of Idraparinux.Investigational
GestodeneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Idraparinux.Experimental
HeminHemin may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Idraparinux.Experimental
HeparinHeparin may increase the anticoagulant activities of Idraparinux.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Idraparinux.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Idraparinux.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Idraparinux.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Idraparinux is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Idraparinux.Approved
IbudilastIbudilast may increase the anticoagulant activities of Idraparinux.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Idraparinux.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Idraparinux.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Nutraceutical
IfenprodilIfenprodil may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Idraparinux.Investigational
IloprostIloprost may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Idraparinux.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Idraparinux.Approved
IndobufenIndobufen may increase the anticoagulant activities of Idraparinux.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Idraparinux.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Idraparinux.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Idraparinux.Experimental
IsoxicamIsoxicam may increase the anticoagulant activities of Idraparinux.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Idraparinux.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Idraparinux.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Idraparinux.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Idraparinux.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Idraparinux.Approved
LetaxabanIdraparinux may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Idraparinux.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Idraparinux.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Idraparinux.Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Idraparinux.Experimental
LonazolacLonazolac may increase the anticoagulant activities of Idraparinux.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Idraparinux.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Idraparinux.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Idraparinux.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Idraparinux.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Idraparinux.Approved
Megestrol acetateThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranIdraparinux may increase the anticoagulant activities of Melagatran.Experimental
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Idraparinux.Experimental, Investigational
MeloxicamMeloxicam may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Idraparinux.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Idraparinux.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Idraparinux.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Idraparinux.Approved
MethylestrenoloneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Methylestrenolone.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Idraparinux.Approved, Illicit
MilrinoneMilrinone may increase the anticoagulant activities of Idraparinux.Approved
MizoribineMizoribine may increase the anticoagulant activities of Idraparinux.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Idraparinux.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Idraparinux.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Idraparinux.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Idraparinux.Approved
NadroparinIdraparinux may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Idraparinux.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Idraparinux.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Idraparinux.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Idraparinux.Approved, Withdrawn
NepafenacNepafenac may increase the anticoagulant activities of Idraparinux.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Idraparinux.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Idraparinux.Approved
NimesulideNimesulide may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Idraparinux is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Idraparinux.Investigational
NomegestrolThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Idraparinux.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Idraparinux is combined with Obinutuzumab.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Idraparinux.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Idraparinux.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Idraparinux is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Idraparinux.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Idraparinux can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Idraparinux.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Idraparinux.Vet Approved
OtamixabanIdraparinux may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Idraparinux.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Idraparinux.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Idraparinux.Investigational
ParecoxibParecoxib may increase the anticoagulant activities of Idraparinux.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Idraparinux.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Idraparinux.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Idraparinux.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Idraparinux.Approved, Investigational
PethidineThe risk or severity of adverse effects can be increased when Idraparinux is combined with Pethidine.Approved
PhenindionePhenindione may increase the anticoagulant activities of Idraparinux.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Idraparinux.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Idraparinux.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Idraparinux.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Idraparinux.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Idraparinux.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Idraparinux.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Idraparinux.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Idraparinux.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Idraparinux.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Idraparinux.Approved
ProgesteroneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Idraparinux.Experimental
PromegestoneThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Idraparinux.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Idraparinux.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Idraparinux.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Idraparinux.Experimental
Protein CIdraparinux may increase the anticoagulant activities of Protein C.Approved
Protein S humanIdraparinux may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIdraparinux may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Idraparinux.Approved
PTC299PTC299 may increase the anticoagulant activities of Idraparinux.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Idraparinux.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Idraparinux.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Idraparinux.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Idraparinux.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Idraparinux.Approved, Investigational
ReviparinIdraparinux may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Idraparinux.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Idraparinux.Approved
RivaroxabanIdraparinux may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Idraparinux.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Idraparinux.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Idraparinux.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Idraparinux.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Idraparinux.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Idraparinux.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Idraparinux.Approved
SemapimodSemapimod may increase the anticoagulant activities of Idraparinux.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Idraparinux.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Idraparinux.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Idraparinux.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Idraparinux.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Idraparinux.Approved
SRT501SRT501 may increase the anticoagulant activities of Idraparinux.Investigational
St. John's WortThe metabolism of Idraparinux can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseStreptokinase may increase the anticoagulant activities of Idraparinux.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Idraparinux.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Idraparinux.Approved
SulindacSulindac may increase the anticoagulant activities of Idraparinux.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Idraparinux.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Idraparinux.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Idraparinux.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Idraparinux.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Idraparinux.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Idraparinux.Approved, Investigational
TarenflurbilTarenflurbil may increase the anticoagulant activities of Idraparinux.Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Idraparinux is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Idraparinux.Approved
TenidapTenidap may increase the anticoagulant activities of Idraparinux.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Idraparinux.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Idraparinux.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Idraparinux.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Idraparinux.Investigational
Testosterone cypionateThe therapeutic efficacy of Idraparinux can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Idraparinux can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Idraparinux can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Idraparinux.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Idraparinux.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Idraparinux.Approved
TiboloneTibolone may increase the anticoagulant activities of Idraparinux.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Idraparinux.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Idraparinux.Approved
TinoridineTinoridine may increase the anticoagulant activities of Idraparinux.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Idraparinux.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Idraparinux.Experimental
TipranavirThe serum concentration of Idraparinux can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Idraparinux.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Idraparinux.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Idraparinux.Approved
TositumomabThe risk or severity of adverse effects can be increased when Idraparinux is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Idraparinux.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Idraparinux.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Idraparinux.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Idraparinux.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Idraparinux.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Idraparinux.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Idraparinux.Approved
TriptolideTriptolide may increase the anticoagulant activities of Idraparinux.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Idraparinux.Approved
TroxerutinIdraparinux may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Idraparinux.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Idraparinux.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Idraparinux.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Idraparinux.Approved
WarfarinWarfarin may increase the anticoagulant activities of Idraparinux.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Idraparinux.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Idraparinux.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Idraparinux.Approved
ZileutonZileuton may increase the anticoagulant activities of Idraparinux.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Idraparinux.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Idraparinux

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedNot AvailableDeep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)1
3CompletedTreatmentDeep Venous Thrombosis1
3CompletedTreatmentNonvalvular Atrial Fibrillation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da

Drug created on March 19, 2008 10:29 / Updated on May 02, 2018 01:37